- Home
- HOG vs NAMS Comparison
HOG vs NAMS Comparison
Compare HOG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOG
- NAMS
- Stock Information
- Founded
- HOG 1903
- NAMS 2019
- Country
- HOG United States
- NAMS Netherlands
- Employees
- HOG 5900
- NAMS N/A
- Industry
- HOG Motor Vehicles
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- HOG Consumer Discretionary
- NAMS Health Care
- Exchange
- HOG Nasdaq
- NAMS Nasdaq
- Market Cap
- HOG 3.3B
- NAMS 3.1B
- IPO Year
- HOG N/A
- NAMS N/A
- Fundamental
- Price
- HOG $26.95
- NAMS $35.84
- Analyst Decision
- HOG Buy
- NAMS Strong Buy
- Analyst Count
- HOG 7
- NAMS 10
- Target Price
- HOG $29.14
- NAMS $43.70
- AVG Volume (30 Days)
- HOG 1.3M
- NAMS 1.3M
- Earning Date
- HOG 11-04-2025
- NAMS 11-06-2025
- Dividend Yield
- HOG 2.67%
- NAMS N/A
- EPS Growth
- HOG N/A
- NAMS N/A
- EPS
- HOG 1.93
- NAMS N/A
- Revenue
- HOG $4,474,610,000.00
- NAMS $64,006,000.00
- Revenue This Year
- HOG N/A
- NAMS N/A
- Revenue Next Year
- HOG $3.94
- NAMS N/A
- P/E Ratio
- HOG $13.99
- NAMS N/A
- Revenue Growth
- HOG N/A
- NAMS 762.15
- 52 Week Low
- HOG $20.45
- NAMS $14.06
- 52 Week High
- HOG $35.21
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- HOG 45.71
- NAMS 58.74
- Support Level
- HOG $26.71
- NAMS $34.34
- Resistance Level
- HOG $28.25
- NAMS $37.21
- Average True Range (ATR)
- HOG 0.74
- NAMS 2.52
- MACD
- HOG 0.09
- NAMS -0.39
- Stochastic Oscillator
- HOG 46.50
- NAMS 38.08
About HOG Harley-Davidson Inc.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.